CAR T Cells Continued to Be Leveraged in Lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has shown durable responses in patients with subtypes of non-Hodgkin lymphoma; however, the key to optimizing responses is early referral, said Frederick L. Locke, MD. “It’s important that community … (본문 전체 9/13/2018 4:07 AM)

Leave a Comment